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Abstract 
Understanding how hepatitis C virus (HCV) induces and circumvents the host’s natural killer 
(NK) cell-mediated immunity is of critical importance in efforts to design effective 
therapeutics. We report here the decreased expression of the NKG2D activating receptor as a 
novel strategy adopted by HCV to evade NK-cell mediated responses. We show that chronic 
HCV infection is associated with expression of ligands for NKG2D, the MHC class I-related 
Chain (MIC) molecules, on hepatocytes. However, NKG2D expression is downmodulated on 
circulating NK cells, and consequently NK cell-mediated cytotoxic capacity and interferon-γ 
production are impaired. Using an endotoxin-free recombinant NS5A protein, we show that  
NS5A stimulation of monocytes through TLR4 promotes p38- and PI3 kinase-dependent IL-
10 production, while inhibiting IL-12 production. In turn, IL-10 triggers secretion of TGFβ 
which downmodulates NKG2D expression on NK cells, leading to their impaired effector 
functions. Moreover, culture supernatants of HCV JFH1 replicating Huh-7.5.1 cells reproduce 
the effect of recombinant NS5A on NKG2D downmodulation. Exogenous IL-15 can 
antagonize the TGFβ effect and restore normal NKG2D expression on NK cells. We conclude 
that NKG2D-dependent NK cell functions are modulated during chronic HCV infection, and 
demonstrate that this alteration can be prevented by exogenous IL-15, which could represent a 
meaningful adjuvant for therapeutic intervention. 
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Author summary 
Natural killer (NK) cells are part of the innate immune response against virus infection. Their 
activation is the net result of signals emanating from a panel of inhibitory and activating 
receptors, among which the NKG2D activating receptor plays a major role.  NKG2D ligands, 
the MHC class I related Chain (MIC) molecules, are induced on HCV-infected hepatocytes. 
In this paper, we show that NKG2D expression is decreased on NK cells from chronically-
infected HCV patients. As a consequence, NK cell cytolytic and IFNγ-producing  functions 
are impaired. We show that this phenomenon is mediated by TGFβ produced by monocytes 
upon stimulation by the non structural HCV-NS5A protein.  NS5A could bind to TLR4 on 
monocytes, thus inducing  the production of IL-10 and TGFβ, while inhibiting the production 
of IL-12. We further showed that TLR4-dependent IL-10 production by monocytes upon 
NS5A stimulation was mediated through the p38 and PI3 kinase pathways. In addition, we 
demonstrated that IL-15 could inhibit the TGFβ-mediated effects on NKG2D expression and 
NK cell functions. Collectively, these results identify a new dampening signal used by HCV 
to subvert innate immune response, and may provide new insights into the design of new 
strategies to restore NK cell functions in chronic hepatitis C. 
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INTRODUCTION 
 
Natural Killer (NK) cells are effectors of the rapidly acting antiviral innate immune system. 
They kill virally infected cells and are an important source of  antiviral cytokines such as IFNγ. 
In addition, they establish an early and efficient dialogue with  professional antigen presenting 
cells (APCs) that in turn, orchestrate the adaptive immune response towards Th1-type antiviral 
immunity [1]. NK cell activation is tightly regulated by the integration of signals emanating 
from a diverse array of inhibitory and activating receptors [2]. Inhibitory receptors, including 
Killer cell Immunoglobulin-like receptors (KIRs) and CD94/NKG2A, gauge expression of 
MHC class I molecules which can be compromised by viral immune subversion, and thus 
serves as an indicator of the integrity of cells. Activating receptors, including the natural 
cytotoxicity receptors (NCRs) and NKG2D,  usually detect the presence of infectious non-self 
and/or stress-induced self ligands at the surface of infected cells.  
Hepatitis C virus (HCV), which replicates in hepatocytes, mediates a chronic liver infection in 
the majority of infected individuals. NK cells abound in the normal liver, where they make up 
to 30% of resident hepatic lymphocytes [3]. This huge amount of NK cells in the liver suggests 
that they are important sentinel cells, surveying the liver for signs of damage or cellular stress. 
However, it also implies that HCV must divert NK cell-mediated responses in order to 
establish persistent infection. The importance of NK cells in the resolution of HCV infection is 
illustrated by the influence of genetic polymorphisms of KIR and their HLA ligands on the 
outcome of HCV infection [4]. Various alterations of NK cell phenotype have been described 
during chronic HCV infection, but results are often contradictory regarding the experimental 
conditions used (ex vivo or in vitro cytokine-stimulated), the modifications involved and their 
consequences on effector functions [5,6,7,8,9,10,11].  
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The NKG2D activating receptor is constitutively expressed on human NK and CD8 T cells 
[12]. Its ligands, the MHC class I chain-related A and B proteins (MICA and MICB) and UL-
16 binding proteins (ULBP1-4), are almost undetectable in normal tissues, but are induced on 
the cell surface by various stresses such as DNA damage, tumor transformation and 
intracellular infection. The importance of the NKG2D defense system is highlighted by the 
observation that tumors and viruses have developed several mechanisms for evading NKG2D-
mediated recognition [13,14,15,16,17]. The overall contribution of the NKG2D pathway in the 
control of HCV infection is unclear [7,10]. We show here that NKG2D is downmodulated on 
circulating NK cells, and consequently NK cells are functionally impaired. This defect is 
mediated by the HCV-NS5A protein which disturbs the equilibrium between pro- and anti-
inflammatory monocyte-derived cytokines.  
 
RESULTS 
 
NKG2D expression  is decreased on circulating NK cells during chronic HCV infection 
MIC proteins are induced at the cell surface upon exposure to various pathogens [11,18,19,20], 
serving as a warning signal that alerts NK cells to mediate effector functions through NKG2D 
signaling. We thus examined if MIC was expressed in the liver during chronic HCV infection. 
While staining of control livers showed a faint expression  of MIC in the cytoplasm of some 
hepatocytes and Kupffer cells only, HCV-infected livers displayed a strong and diffuse 
expression of MIC in the cytoplasm and at the surface of HCV-infected hepatocytes, and also 
in some uninfected hepatocytes and large mononuclear cells in portal spaces resembling 
macrophages (Figure 1).  
NKG2D is constitutively expressed on NK cells, and should therefore mediate recognition and 
destruction of MIC-expressing cells. Due to the restricted availability of fresh HCV-infected 
liver samples to isolate infiltrating NK cells, we examined the expression of NKG2D on 
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circulating NK cells. No significant difference in the percentage of circulating NK cells, or in 
the proportion of CD56bright/CD56dim cells was detectable between patients and controls (data 
not shown). The percentage of NKG2D-expressing NK cells was similar in HCV patients and 
healthy controls (> 95% of NK cells in both groups). However, a decreased expression of 
NKG2D on both CD56bright and CD56dim NK cells was detected in HCV viremic patients as 
compared with healthy controls (mean MFI: 61 ± 15 versus 93 ± 25, P< 10-4), HCV patients 
with sustained viral response (SVR) after treatment (81 ± 14, P< 10-3) or patients with non-
infectious chronic inflammatory liver disease (87.4 ± 24.5, P< 10-3) (Figure 2a). Although 
showing some variability among viremic patients, NKG2D levels were not correlated with age, 
sex, HCV viral load, genotype,  ALT levels,  liver fibrosis or activity score.   
To evaluate the functional consequences of this NKG2D reduction, we quantified NK cell 
IFNγ production and CD107a degranulation by flow cytometry. Freshly purified circulating 
NK cells from HCV patients showed impaired IFNγ production in the presence of MHC class 
I-negative K562 as compared to NK cells from healthy controls. In addition, NK cells from 
HCV patients showed a two-fold decreased degranulation in the presence of K562 targets 
(mean CD107 expression 29.3% ± 2.7 in controls compared to 15.9% ± 2.9 in patients, P = 
0.003) (Figure 2b). This defective NK cell function was at least in part dependent on NKG2D, 
as shown using C1R-MICA as target cells. CD107a expression on NK cells positively 
correlated with NKG2D levels (Spearman rho (r) = 0.62, P = 0.008, Supplementary Figure S1). 
Moreover, NKG2D blocking by anti-NKG2D antibody largely inhibited inhibited NK cell 
degranulation in both HCV patients and healthy controls (Figure 2c). That NK cell 
degranulation was not fully abrogated indicates however, that it likely involves other activating 
receptor(s) in addition to NKG2D. Altogether, these results suggest that the signaling pathway 
initiated by NKG2D on target exposure may not operate properly in HCV patients due to 
NKG2D reduction on NK cells. 
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Soluble TGFβ is associated with NKG2D reduction. 
Systemic NKG2D downregulation on immune effector cells has been related to the release of 
soluble factors such as MIC molecules (sMIC) in the serum of cancer patients [13]. We 
measured sMIC in the serum of HCV patients and healthy controls, and found similar low 
levels of sMIC in both groups (data not shown). TGFβ is another mediator of systemic 
NKG2D downregulation [21,22,23]. Total TGFβ  levels were higher in the serum of HCV-
infected patients compared to controls and SVR patients  (Figure 3a).  An inverse linear 
relationship was observed between TGFβ and NKG2D levels on NK cells (Figure 3b). To 
investigate whether serum of HCV patients could mimic the effect of exogenous TGFβ on 
NKG2D expression, we incubated control NK cells with recombinant TGFβ or with serum 
from representative HCV patients with known TGFβ concentration, and analyzed NKG2D 
expression. NKG2D levels were reduced in a TGFβ  concentration-dependent manner, and 
were largely restored when incubation was performed in the presence of neutralizing anti-
TGFβ  antibody (Figure 3c).  
 
TGFβ is secreted by monocytes upon stimulation by the HCV-NS5A protein  
Engagement of the HCV receptor CD81 by the major HCV envelope protein E2 was shown to 
block NK cell functions triggered by NKG2D engagement [24]. We thus hypothesized that 
HCV-E2 might modulate NKG2D expression. PBMCs from normal donors were exposed to 
recombinant HCV-E2, as well as to other structural and non-structural HCV proteins for 6 to 
48 hr, and NKG2D levels were measured on NK cells (Figure 4a). While HCV-E2, -core, -
NS3, or -NS4 proteins had no or minor effect, HCV-NS5 induced a dose-dependent reduction 
of NKG2D on NK cells, which was maximal at 48 hr. Using different recombinant NS5A 
preparations (E. Coli-derived full length NS5, yeast-derived NS5 2054-2995 or E. Coli-
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derived NS5A amino acid 2061-2392), we reproducibly identified the NS5A protein as being 
responsible for this effect. At a concentration of 0.5 μg/ml, NS5A reduced NKG2D 
expression by 40% (P = 0.001), which was of the same order of magnitude as 10 ng/ml of 
recombinant TGFβ used as positive control. Of note, NS5A stimulation also induced 
downmodulation of the NKp30 activating receptor (Supplementary Figure S2), in line with 
the previously described effect of TGFβ on NKp30 expression [23]. The β2-microglobulin, 
used as control for irrelevant protein produced in E. Coli, had no effect on NKG2D 
expression. All recombinant proteins used were tested for the absence of significant 
lipopolysaccharide (LPS) contamination (0.054 endotoxin unit/μg recombinant protein in the 
case of NS5A, i.e. 5.4 pg/μg protein). In addition, pretreating NS5A by 10 μg/ml of 
polymyxin B was without effect, ruling out the possibility of contaminating LPS being the 
factor responsible for NKG2D reduction. Inactivation of the NS5A protein by freeze/thaw 
before incubation with PBMCs abolished the NS5A-mediated NKG2D reduction, suggesting 
that it required intact protein conformation.  
To verify that NS5A-mediated downregulation of NKG2D on NK cells was accompanied by a 
decrease in their functional capacity, PBMCs were exposed to NS5A, NS4 or medium alone 
for  48 h, after which NK cell degranulation capacity in the presence of K562 target cells was 
evaluated by flow cytometry. The presence of NS5A in PBMC culture induced a  significant 
decrease of CD107a expression on NK cells, while NS4 had no effect, confirming that NS5A 
is responsible for a decreased functionality of NK cells  (Figure 4b).  
We then measured the TGFβ concentration in culture supernatants from PBMCs exposed to 
NS5A or medium alone for 12 to 48h. Levels of TGFβ progressively increased in the presence 
of NS5A (Figure 4c). To confirm that the NS5A effect was indeed related to TGFβ production, 
we pretreated PBMCs with anti-TGFβ antibody prior to stimulation with NS5A. Blocking 
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TGFβ abrogated the NS5A-induced reduction of NKG2D on NK cells in a dose-dependent 
way (Figure 4d).  
When similar experiments were performed on freshly-purified NK cells, NS5A stimulation 
failed to downmodulate NKG2D, suggesting that TGFβ was likely produced by a distinct cell 
population among PBMCs. To identify the source of TGFβ, we cocultured purified NK cells 
with different components of autologous PBMCs, including adherent or non adherent cells, 
monocyte-depleted PBMCs, or purified monocytes. Cells were stimulated for 6-48 hr with 
NS5A, after which NKG2D was measured on NK cells. At the same times, culture 
supernatants were recovered and were assayed for TGFβ production. As shown in Figure 4e, 
only monocyte-containing populations induced a significant decrease of NKG2D expression on 
NK cells (p<0.002). Notably, downregulation  of NKG2D was completely lost in the Transwell 
system, indicating that monocyte-NK cell contacts were required for this effect. NKG2D 
reduction was accompanied by an increased production of TGFβ in cell supernatants, which  
was maximal after 40 hr of NS5A stimulation (Figure 4c). In addition, neutralization of TGFβ 
in the coculture system of monocytes and NK cells fully restored NKG2D expression on NK 
cells. Altogether, these results indicate that NS5A protein induces TGFβ production by 
monocytes, which in turn affects NKG2D expression and inhibits NK cell functions.  
 
NS5A augments IL-10 and suppresses IL-12 production by monocytes 
Activation of monocytes by microbial products usually induces the production of IL-12, and to 
a lesser extent of IL-10. We thus wondered if the ability of NS5A to regulate the production of 
TGFβ was more global, and measured the production of IL-10 and IL-12 in supernatants from 
control monocytes stimulated for 24 to 48 h with NS5A, NS4, medium alone, or LPS as a 
positive control. High levels of IL-10 (> 1400 pg/ml) were detected 24 hr after NS5A 
stimulation (Figure 5a, left panel). These levels were of the same order of magnitude as those 
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induced by 1 μg/ml of LPS.  We then wondered if NS5A-induced TGFβ production was 
related to autocrine IL-10 release. Blocking IL-10 or its receptor abrogated the NS5A-induced 
TGFβ secretion in a dose-dependent manner, but did not modify the basal TGFβ production by 
monocytes (Figure 5a, right panel). Futhermore, we found elevated IL-10 levels in the sera of 
HCV patients, that were positively correlated with TGFβ levels  (r = 0.39, P = 0.016).  
By contrast, very low amounts of IL-12 were detected in supernatants of NS5A-stimulated 
monocytes, while LPS induced high levels of IL-12 as expected (Figure 5b). We thus 
hypothesized that NS5A might inhibit the LPS-induced production of IL-12 by monocytes. 
Indeed, pretreatment of monocytes by NS5A strongly inhibited IL-12 production upon LPS 
stimulation.  
Taken together, these findings demonstrate that NS5A potently increases the production of 
anti-inflammatory cytokines IL-10 and TGFβ, while concurrently suppressing the production 
of proinflammatory IL-12. The lack of NS5A-induced IL-12 secretion also confirms that LPS 
contamination is not responsible for the NS5A-mediated effect in monocytes. 
 
NS5A interaction with TLR4 instructs monocytes to preferentially induce IL-10 secretion 
NK cell activation requires signals provided by APCs that sense pathogen products through 
conserved pattern-recognition receptors such as Toll-like receptors (TLRs). In particular, TLR2 
and TLR4 are involved in extracellular sensing of several viral proteins by  monocytes and 
dendritic cells [25,26,27]. We thus hypothesized that NS5A might interact with TLR2 or TLR4 
signaling in monocytes. Pretreating monocytes with blocking anti-TLR4 antibody, or with 
antibody to the TLR4 associated molecule CD14, fully abolished NS5A-mediated IL-10 
production, while blocking anti-TLR2 antibody had no effect (Figure 5c). This suggested that 
NS5A might interact with TLR4 on monocytes. To support this hypothesis, freshly purified 
monocytes were incubated at 4°C with NS5A or NS4, and binding was revealed by staining 
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with anti-NS5A antibody and flow cytometry analysis. A significant binding of NS5A on 
monocytes was observed, that was inhibited by almost 50% in the presence of blocking anti-
TLR4 antibody (Figure 5d). 
TLR4 signaling results in the downstream activation of NF-kB, MAPK (p38 and JNK) and 
PI3K pathways [28]. TLR4 activation may contribute to IL-10 production via p38 and PI3K 
[29], while PI3K is an endogenous suppressor of IL-12 production triggered by TLR4 [30]. We 
pretreated monocytes with pharmacological inhibitors of signaling molecules prior to 
stimulation with NS5A, and measured IL-10 production. Inhibition of  p38 or PI3K suppressed 
NS5A-induced production of IL-10 in a dose-dependent way, while other inhibitors had no or 
minor effects (Figure 5e).  
Altogether, our results indicate that, upon NS5A interaction with TLR4, monocytes 
preferentially secrete IL-10 through activation of  the p38 and PI3 kinase pathways, but are 
prevented from secreting IL-12. 
 
NS5A mediates the NKG2D-downregulating effect in supernatants of HCV-infected cells  
NS5A is not found in viral particles secreted by infected cells, which raises the question of its 
availability in the extracellular medium. However, it is becoming increasingly clear that HCV 
infection of hepatocytes has direct cytopathic effects, suggesting that NS5A might be released 
from apoptotic/necrotic infected cells  [31,32,33]. To verify this hypothesis, we determined 
whether supernatants of HCV-infected cells induced downmodulation of NKG2D. To this 
aim, we used Huh-7.5.1 hepatoma cells transfected or not with the infectious genotype 2a 
JHF1 replicon [34,35]. Control PBMCs were cultured for 48h with Huh-7.5.1 culture 
supernatants or with recombinant NS5A as positive control, after which NKG2D levels on 
NK cells were measured (Figure 6a). Supernatants from Huh-7.5.1 uninfected cells, or those 
recovered as soon as day 3 post transfection, did not modify NKG2D levels. By contrast, 
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supernatants recovered on days 13, 15 and 18 post transfection reproducibly induced 
downmodulation of NKG2D at levels similar to those obtained using 0.5 μg/ml rNS5A. At 
these time points, the majority of cells in the culture expressed HCV proteins, infectivity titers 
in culture supernatant were maximal, and cytopathic effects were observed, as reported [31]. 
Notably, there was no effect of supernatants recovered at day 23, i.e. at a time cells were 
cytologically normal and levels of extracellular infectious virus had declined.  
To rule out the possibility that this effect was mediated by TGFβ, we quantified TGFβ in 
Huh-7.5.1 culture supernatants. In all conditions studied, TGFβ levels were below 40 pg/ml 
and could thus not be responsible for the observed NKG2D-downregulating activity. Taken 
together, these data indirectly suggested that NS5A is released by HCV-replicating cells, most 
likely among cell debris generated by infection.  
Since we previously observed a specific binding of recombinant NS5A on monocytes, we 
incubated control PBMCs with supernatants from uninfected or infected Huh-7.5.1 cells, or 
with recombinant NS5A or NS4 proteins, after which NS5A binding to monocytes was 
evaluated by staining with anti-NS5A antibody. Supernatants from uninfected cells, or 
supernatants recovered on days 2 and 23 post transfection did not show any binding signal, in 
accordance with their lack of NKG2D-downregulating activity. However, supernatants 
recovered on day 12 post transfection gave a binding signal that was of the same order of 
magnitude than that observed with recombinant NS5A. (Figure 6b). Notably, this effect was 
abrogated when day 12  supernatants were filtered in order to eliminate cell debris, suggesting 
that NS5A was not released from JHF1-replicating Huh-7.5.1 cells in a soluble form, but was 
rather associated with apoptotic-cell components. Our attempts to corroborate the presence of 
NS5A in day 12 supernatants using ELISA or Western blot techniques, or to deplete NS5A 
from these supernatants using anti-NS5A antibody, were unsuccessful (data not shown). This 
could be due to the fact that NS5A was not easily recognized by the 9E10 mAb when 
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associated with apoptotic cell debris in the supernatants. Alternatively, it could be that a 
fraction of bioactive NS5A becomes liberated after interaction of the cell debris with 
monocytes.  
 
Liver NK cells paradoxically express high NKG2D levels  
Given that apoptotic HCV-replicating cells seem to release NS5A, we made an effort to resolve 
the issue of NKG2D expression on NK cells in the infected liver.  We analyzed liver-
infiltrating NK cells and paired circulating NK cells in 11 additional HCV viremic patients 
who underwent liver biopsy for diagnostic purpose. NKG2D levels on peripheral NK cells 
fully matched with those in the first series of patients (MFI 59 ±7.7 and 61 ± 15, respectively). 
Of note, the proportion of NK cells among liver-infiltrating mononuclear cells was very low 
(2.7% ± 0.7%), as already reported in HCV-infected livers [9,36,37]. To our surprise - but in 
line with previous observations in the rat and human ([10,38,39]- liver NK cells expressed 
higher NKG2D levels than their circulating counterpart (mean MFI 115.5 ±17.4 versus 59 ± 
7.7, P = 0.002, Wilcoxon matched-pairs test). NKG2D analysis in a representative liver sample 
is shown in Figure 6c (left panel) and Supplementary Figure S3. By comparison, NKG2D 
levels on liver NK cells from 8 control patients with non-infectious chronic inflammatory liver 
disease were not significantly different from those observed on circulating NK cells (mean 
MFI 106.2 and 87, respectively). Staining of HCV-infected liver sections showed that 
NKG2D+ cells were indeed very scarce even among large portal infiltrates. Only few cells 
were found positive in sinusoidal tracts (Figure 6c, right panel). Similar to what was observed 
for circulating NK cells, the proportion of liver NK cells and their NKG2D levels were not 
correlated with any HCV disease marker (not shown). 
Whether these intrahepatic NKG2Dhigh NK cells were more functionally competent than their 
circulating counterpart could not be evaluated due to their too small number. In attempt to 
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analyze NKG2D-mediated functions in a clinically relevant target cell system, we sought to 
use JHF1-infected Huh-7.5.1 cells. However, it turned out that these cells were not pertinent 
for NKG2D ligand expression studies. Not only HCV infection did not induce MIC 
expression on Huh7.5.1 cells, but none of the stimuli known to be potent inducers of NKG2D 
ligands (heat-shock, oxidative stress, γ-radiation, retinoic acid, inhibitors of histone 
deacetylase) was able to induce MIC surface expression on Huh7.5.1 cells (data not shown).  
 
IL-15 can antagonize the TGFβ-mediated modulation of NKG2D and NK cell functions  
In contrast with TGFβ, IL-15 up-regulates surface NKG2D expression [40]. Because of the 
reciprocal antagonism of IL-15 and TGFβ on intracellular signaling pathways [41,42,43], we 
wondered if decreased NKG2D expression on circulating NK cells from HCV patients might 
be amplified by a resistance of NK cells to endogenous IL-15 due to TGFβ or by a defective 
production of IL-15 in response to infection. PBMCs from healthy controls or HCV patients 
were pretreated with IL-15 for 24 hr after which NKG2D staining was performed (Figure 7a). 
IL-15 restored NKG2D expression on patients’ NK cells at levels similar to those usually 
observed in controls, indicating that NK cells from HCV patients were normally responsive to 
IL-15. Moreover, IL-15 fully antagonized the NS5A-induced downmodulation of NKG2D on 
NK cells. Even in the presence of TGFβ-containing serum, IL-15 could prevent NKG2D 
expression. Furthermore, both NK cells from HCV patients and  TGFβ-stimulated control NK 
cells exhibited a significant enhancement of cytotoxicity upon IL-15 stimulation (Figure 7b).  
Given that pathogen components are among the stimuli that elicit production of IL-15, one 
could expect elevated levels of IL-15 in the serum of chronic HCV patients. IL-15 levels were 
not higher in patients than in controls (mean 7.61 ± 1.93 pg/ml, and 7.98 ± 1.40 pg/ml, 
respectively; ns). It must be noted, however, that IL-15 is mostly present in membrane-bound 
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IL-15/IL-15Rα complexes [44], so that free IL-15 is unlikely to represent a reliable marker of 
systemic IL-15 production. 
Altogether, these data suggest that overexpression of TGFβ contributes to the reduction of 
NKG2D and defective functions of circulating NK cells in HCV patients, a defect which can 
be antagonized by exogenous IL-15.   
 
DISCUSSION 
  
HCV uses a repertoire of dampening signals to subvert immune responses, a significant 
number of which target the innate system [45,46]. We report here an altered expression of the 
NKG2D receptor as an additional HCV strategy to avoid NK-cell mediated recognition. 
HCV-NS5A protein, through monocyte-derived TGFβ production, downregulates expression 
of NKG2D on NK cells, thus reducing their cytotoxic potential and IFNγ production. Some 
previous studies have reported defective NK cell function in HCV infection [47,48,49], 
although others have not seen this [5,50,51]. Different methodologies, including the use of 
total PBMC or purified NK cells, fresh or cryopreserved cells, unstimulated or cytokine-
stimulated cells, chromium release or flow cytometry assays, and small sample sizes, might 
explain why some of the findings in these studies differed from our own. We performed all 
experiments on freshly-purified unstimulated NK cells, and measured NK cell degranulation 
rather than overall K562 cell lysis, because it has the advantage to shift the focus from the fate 
of target cells  to the true response of NK cells, as previously demonstrated [52].  
Different virally-encoded products have been shown to impair NKG2D-mediated detection of 
infected cells, usually by targeting the ligands of NKG2D rather than the receptor itself 
[14,16,53,54]. HCV only encodes a small number of structural and non-structural proteins. 
Consequently, each HCV gene product must have pleiotropic functions rather than highly 
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specialized ones. Targeting NKG2D rather than its numerous ligands is at lower cost for 
HCV. However, it is likely that HCV must also target other receptors to escape NK cell 
recognition. Indeed, reduced NKp30 levels have been observed on NK cells from HCV 
patients [6]. Interestingly, TGFβ not only downmodulates NKG2D, but also reduces 
expression of NKp30 [23] and we observed a TGFβ-mediated reduction of NKp30 on control 
NK cells upon NS5A stimulation. This pleiotropic effect of TGFβ thus represents an 
economical way for HCV to shift the overall balance of NK signals towards an inhibitory 
phenotype. Our results are in contrast with a recent report by Oliviero et al. showing an 
increased proportion of NKG2D+ NK cells in HCV patients compared with healthy controls 
[10]. A potential explanation to this discrepancy is the surprisingly low frequency of NKG2D-
positive NK cells in controls (60%) from Oliviero’s study, although NKG2D is usually 
reported to be constitutively expressed on all NK cells [12]. In our study , the differences in 
patients and controls only affected NKG2D expression levels, but not the frequency of 
NKG2D-positive cells. 
We show that TGFβ production results from NS5A interaction with the TLR4 complex on 
monocytes, which leads to a dysregulated equilibrium of inflammatory cytokines, i.e. increased 
IL-10 and defective IL-12 production. IL-10 is a potent suppressor of TLR-induced 
inflammatory responses, and an important target of immune subversion for some pathogens. 
IL-10 signaling activates STAT3, which positively regulates TGFβ promoter activity [55]. 
Previous studied identified that HCV core, NS3 or NS4, but not E2 protein induced monocyte-
derived IL-10 production [56,57]. In the case of core and NS3, this effect was mediated 
through TLR2 signaling [58]. Unfortunately, NS5A was not tested in these studies. We think 
that NS5A signals through TLR4 in monocytes, because preincubation with a blocking anti-
TLR4 mAb inhibited NS5A-mediated IL-10 production. Also, binding experiments showed 
that NS5A interacted directly with TLR4 on monocytes. The likelihood of contaminating LPS 
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contributing to the NS5A-mediated effect was ruled out by the lack of concomitant IL-12 
production. The downregulation  of NKG2D required direct monocyte-NK cell contacts, as it 
was completely lost in the Transwell system. This suggests that, in addition to produce soluble 
TGFβ, NS5A-stimulated monocytes might express membrane-bound TGFβ which would 
further participate in NKG2D modulation through direct contact with NK cells. In support of 
this hypothesis, myeloid-derived suppressor cells (MDSCs), a subpopulation of immature 
myeloid cells with suppressor functions, were shown to downregulate NKG2D expression and 
inhibit liver NK cell cytotoxicity in cancer-bearing mice, through expression of membrane-
bound TGFβ and direct contact with NK cells [59]. Furthermore, MDSCs were recently shown 
to inhibit NK cell functions through direct cell-cell contact in the context of hepatocellular 
carcimoma in humans [60,61]. Whether a subpopulation of NS5A-binding monocytes 
characterizes MDSCs able to suppress NK cell activity through TGFβ production is under 
investigation in our laboratory. Further studies will be needed to determine the role of MDSCs 
in HCV-infected patients.  
The effect of NS5A on monocytes is reminiscent of other proteins from persistent viruses. 
Interaction of HTLV-1 p30 protein with TLR4 signaling stimulates the release of IL-10 and 
hampers the release of pro-inflammatory cytokines from macrophages [25]. HIV Tat-induced 
IL-10 production by monocytes is regulated by p38 MAPK [62]. The LMP1 protein of EBV 
also induces IL-10 via p38 and PI3 kinase activation [63]. The vaccinia virus A52R protein 
activates p38 and JNK, and promotes TLR4-induced IL-10 production, while inhibiting NFkB-
dependent genes IL-8 and RANTES [64]. Human major group rhinoviruses [26] 
downmodulate the accessory function of monocytes by inducing IL-10 production and 
inhibiting IL-12 production. Together, those reports and our findings open the idea that 
engagement of TLR4 may generate negative signals that are necessary for immune subversion 
and viral persistence.  
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NS5A is localized in the perinuclear regions of the infected cell, but is not present in the 
circulating virions. However, there is now increasing evidence that HCV mediates hepatocyte 
apoptosis [31,32,33,65,66], which may allow HCV proteins to be released in the extracellular 
milieu. We observed that supernatants of Huh7.5.1 human hepatoma cells transfected with the 
JFH1 infectious replicon reproduced the effect of recombinant NS5A on NKG2D 
downmodulation, suggesting that NS5A might be released in the culture medium from 
apoptotic cells. However, direct proof for the presence of NS5A protein in HCV-infected cell 
supernatants is still lacking, as it was not accessible by anti-NS5A mAb in Western blot or 
depleting experiments. The possibility that a fraction of bioactive NS5A only becomes 
liberated after interaction of the cell debris with monocytes is supported by our observation of 
a comparable NS5A binding on monocytes of recombinant protein and of supernatants from 
JFH1-replicating Huh7.5.1 cells. 
To reconcile this idea with our finding that the rare NK cells present in HCV-infected liver 
expressed high NKG2D levels, one may envision a scenario in which the local cytokine 
microenvironment  of the liver sinusoids, in particular IL-15 (which is produced by Kupffer 
cells) can inhibit the effect of TGFβ and enhance NKG2D expression. Indeed, IL-15 
antagonizes the TGFβ immunosuppressive effects through blockade of the Smad3 signaling 
pathway [41,42,43]. Expression of IL-15 within HCV-infected livers was reported to show a 
sinusoidal distribution [67]. We found that the rare intrahepatic NKG2D-positive cells were 
located in sinusoidal tracts, but not in parenchymatous areas or necroinflammatory lesions 
where NS5A release by apoptotic infected cells is likely to occur. Moreover, we showed that 
IL-15 could fully prevent the TGFβ-mediated modulation of NKG2D and NK cell functions 
in vitro. A possibility is that once having migrated to areas of inflammation in the liver, most 
NK cells would be induced to apoptosis. This phenomenon might be favored by the abnormal 
expression of the Programmed-Death 1 (PD-1) molecule on NK cells, which has been 
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observed in chronically-infected HCV patients [68]. Only NK cells expressing high levels of 
NKG2D would preferentially home to the liver, or could survive in the liver due to their 
resistance to apoptosis under inflammatory conditions. This hypothesis is the matter of current 
investigation in our laboratory. That NKG2D levels, either on peripheral or liver-infiltrating 
cells, were not correlated with virological or histological markers of the liver disease has also 
been observed by others [39] and might reflect such complex interactions. Unfortunately, our 
attempt to clarify whether increased NKG2D expression on liver NK cells is associated with 
enhanced cytotoxic activity was hindered by the highly restricted access to fresh liver biopsy 
tissue from chronically infected patients. The availability of noninvasive biomarkers for first-
line assessment of liver fibrosis has led to a dramatic decrease in the use of liver biopsy for 
patients with chronic hepatitis C. Regrettably, functional analysis of liver-infiltrating immune 
cells in the few patients still undergoing liver biopsy is probably not representative of natural 
HCV infection.  
 Altogether, our observations raise the idea that reducing IL-10 and/or TGFβ 
bioavailability could be a suitable means to restore NK cell functions in chronic hepatitis C. 
However such approach could dangerously modify the overall equilibrium between effector 
and regulatory mechanisms. Rather, we propose the use of IL-15 - or biologically active 
soluble IL-15/IL-15Rα complexes [69] - as an adjuvant  therapeutic agent to restore NKG2D-
mediated NK cell functions. Notably, the pathways triggered by IL-15 receptor signaling are 
required for the NKG2D-mediated signal transduction and cytotoxicity [70]. Jinushi et al. 
showed that DCs from HCV-infected patients have impaired IL-15 production upon 
stimulation by IFNα [71]. Given the role of NK cells in promoting optimal initiation of 
adaptive CD8 T cell responses, and the role of IL-15 in the proliferation and survival of NK 
and CD8 T cells, IL-15 might help not only in establishing strong innate responses, but also in 
inducing more robust antiviral CTL responses.  
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MATERIAL AND METHODS 
Subjects 
The HCV viremic patient group consisted of 34 chronically infected patients (anti-HCV 
antibodies and HCV RNA positive) who were naive of treatment, or who discontinued 
treatment at least 6 months before study. The HCV aviremic group was composed of 9 
subjects with sustained viral response (SVR) following IFNα and/or ribavirin therapy, with 
viremia remaining undetectable for at least 6 months at the time of study. The main clinical 
characteristics of the patients are shown in Table 1. Patients with primary biliary cirrhosis (n= 
4) or autoimmune hepatitis (n= 5) were used as non-infectious chronic inflammatory liver 
disease controls. An additional series of 11 HCV viremic patients was studied for paired 
analysis of circulating and liver-infiltrating mononuclear cells. The control group consisted of 
23 age and sex matched blood donor volunteers seronegative for HCV.  
 
Ethics Statement 
The study was performed in accordance with the Declaration of Helsinki and French 
legislation, and received approval of the Grenoble University Hospital ethical committee 
(03/APTF/1). Written informed consent was provided by all study participants. 
 
Flow cytometry 
Blood samples were processed within 2 h of collection and PBMCs were separated by 
Lymphoprep gradient centrifugation (Biowest). NK cells or monocytes were freshly purified 
from PBMCs by negative selection using magnetic microbead separation kits (Miltenyi 
Biotec) with purity higher than 90%. Liver-infiltrating mononuclear cells were isolated from 
fresh biopsy as reported [72] and processed immediately for staining and flow cytometry. 
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Cells were incubated for 20 min at 4°C with combinations of the following antibodies: CD3-
FITC, CD56-PE, CD8- or CD4-PerCP (BD Biosciences); NKG2D-APC or isotype-matched 
control antibodies of irrelevant specificity (BD PharMingen). Cells were fixed in 1% 
formaldehyde and analyzed on FACSCalibur (BD Biosciences), collecting a total of 100,000 
events in a live gate, and data were analyzed using FlowJo software.  
 
NK cell degranulation assay and IFNγ production 
NK cell cytototoxic potential was studied using CD107a as a marker of degranulation. Freshly 
isolated NK cells were incubated in the presence or absence of K562 cells, C1R cells or C1R-
MICA transfectants (a generous gift from A. Toubert, Hopital St-Louis, Paris, France) as 
target cells. CD107a-Pe-Cy5 antibody (BD) was added directly to the tubes at 20 µg/mL. 
After 1 hour at 37°C in 5% CO2, brefeldin A (10 µg/ml, Sigma) and monensin (6 µg/ml, 
Sigma) were added for additional 5 hr, and cells were stained with CD3-FITC and CD56-PE 
antibodies, fixed and analyzed by flow cytometry. Where indicated, NKG2D blocking 
antibody (20 μg/ml, Coulter Immunotech) was added. For intracellular IFNγ analysis, NK 
cells were incubated for 6 hr with K562 cells, fixed following staining with anti-CD3 and 
anti-CD56, permeabilized with 0.2% saponin and stained with IFNγ-PE antibody  (BD) for an 
additional 30 min.  
 
Cell cultures and reagents 
Recombinant TGFβ and IL-15 were purchased from R&D Systems. Cytokine levels were 
quantified using ELISA (TGFβ, IL-10 and IL-15 quantikine kits from R&D Systems;  IL-12 
ELISA kit from  Diaclone). Soluble MICA was measured in the sera with a sandwich ELISA 
as described  [73]. Recombinant soluble MICA was consistently detected at concentration of 
0.2 ng/ml.  
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The following genotype 1a-derived  recombinant HCV proteins were used: E. Coli-derived 
full length core, NS3, NS4 and NS5 (Axxora LKT). In confirmatory experiments, we used E. 
Coli-derived rNS5A amino acid 2061-2392 (Axxora LKT) and yeast-derived rNS5 2054-2995 
(ibtsystems). Recombinant HCV-E2 protein (Immunodiagnostics) was purified from 
baculovirus-infected insect cells. β2microglubulin was used as control for E. Coli-purified 
protein. All proteins were used at a final concentration of 0.1 to 1 µg/ml. Endotoxin levels 
determined by the limulus amebocyte lysate assay (BioWhittaker Cambrex) were between 
0.05 and 0.2 endotoxin unit/μg protein (0.054 EU/μg for the full length NS5A protein from 
Axxora LKT used in most experiments). To ensure that trace amount of endotoxin did not 
contribute to the observed responses, rNS5A was subjected to polymyxin B (10 μg/ml) 
(Sigma–Aldrich, St. Louis, MO, USA) for 15 min at room temperature.  
For blocking experiments, cells were incubated with 10 μg/ml of neutralizing mAb to TLR4, 
TLR2 or CD14 (eBioscience), soluble IL-10 receptor, anti-IL-10 neutralizing antibody (R&D 
Systems) before the addition  of HCV protein. Isotype-matched antibodies were used as 
controls (Coulter Immunotech). Inhibitors of the signaling  molecules JNK (SP600125), p38 
(SB203580), PI3 kinase (LY294002), and MEK1 (U0126) were from Calbiochem.  
 
In vitro  system of HCV replication 
Huh-7.5.1 cells were kindly provided by Pr. Francis V. Chisari (The Scripps Research 
Institute, La Jolla, CA), and grown in Dulbecco’s modified Eagle’s medium-based medium as 
described [35]. Productive HCV infection was achieved as described [34,35]. Briefly, 
Huh-7.5.1 cells were transfected with genomic HCV RNA transcribed in vitro from the 
plasmid pJFH1 [34] (a kind gift from Takaji Wakita, National Institute of Infectious Diseases, 
Tokyo, Japan) used as template, and cells were then passaged when necessary to maintain 
subconfluent cultures throughout the experiment. Cultures were probed for the frequency of 
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HCV protein-expressing cells by in situ immunofluorescence, and infectivity titers in culture 
supernatant were assessed by focus-formation assay [35].  
For binding experiments, monocytes were incubated for 30 min at 4°C with supernatants from 
non infected or JFH1-replicating Huh-7.5.1 cells, or with 0.5 μg/ml of recombinant NS5A 
(positive control) or NS4 (negative control). Where indicated, culture supernatants were 
passed through a 0.45-μm filter following low-speed centrifugation to remove cellular debris. 
After washing and blocking with human IgG, cells were incubated for 40 min at 4°C with the 
mouse 9E10 mAb specific for genotype 2a NS5A (a generous gift from C.M. Rice, 
Rockefeller University, NY, USA) [74], followed with PE-labeled goat anti-mouse Ig, and 
analyzed by flow cytometry. 
Immunostaining of liver tissue 
Expression of MIC was evaluated on liver biopsy samples submitted to the Department of 
Pathology for diagnostic purpose. Paraffin-embedded liver biopsy sections (12 patients) were 
stained with anti-MIC (clone SR99 [75]) or anti-NKG2D (R&D Systems) mAb, followed with 
biotinylated goat anti-mouse Ig. For double immunofluorescence staining, cryosections (3 
patients) were stained overnight at 4°C with anti-HCV-NS5A mAb (clone 7-D4, BioDesign), 
followed with FITC-labeled goat anti-mouse IgG, then incubated with biotinylated anti-MIC 
mAb, followed with streptavidin-Cy3. Slides were mounted with DAPI-containing medium 
(Vector Laboratories) and analyzed by immunofluorescence (Eclipse E888, Nikon) or confocal 
laser scanning (TCS SPS AOBS model, Leica) microscopy. 
Statistical analysis 
All statistical tests were performed using Stata software (version 8.0). Qualitative values 
between groups were compared using the chi-square test or Fisher’s exact test, and quantitative 
values were compared using the non-parametric Mann-Whitney U test. The Wilcoxon test was 
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used to compare matched pairs. Correlation between two variables was determined using 
Spearman’s coefficient (rho). Two-sided P values less than 0.05 were considered significant.  
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 Figure Legends 
 
Figure 1. MIC proteins are overexpressed in HCV-infected liver.  
Staining for MIC proteins in sections of paraffin-embedded (a-d) or cryopreserved (e,f) liver 
biopsies from HCV-negative control (a) or chronically HCV-infected patients (b-f). Control 
isotype is shown in (d). A strong and diffuse expression of MIC (red) is observed in 
hepatocytes from HCV-infected patients, in the cytoplasm (b,c) and at the membrane (e, 
confocal microsope analysis). MIC expression is seen in HCV infected cells (NS5A staining in 
green) and in some adjacent cells (f). Nuclei appear colored in blue. Results are representative 
of 12 patients for paraffin-embedded biopsies, and 3 patients for cryopreserved biopsies. 
Original  magnification, x10 (a,d), x40 (e) and x60 (f). 
 
Figure 2: NKG2D levels and NK cell functions are altered in HCV-infected patients. 
A) Freshly isolated PBMCs were stained with CD56, CD3 and NKG2D mAbs, and analyzed 
by FACS. NK cells were identified by gating on CD3-CD56+ cells. Left panel: Representative 
NKG2D staining in one healthy control (dark line), one chronically-infected HCV patient 
(plain gray) and one HCV patient with sustained viral response (SVR, empty gray). Isotype 
control is shown in dotted line. Right panel: Combined data showing the mean NKG2D levels 
on NK cells from 23 controls, 41 HCV patients, 9 patients with SVR, and 9 patients with non-
infectious inflammatory liver disease (ILD). Data are expressed as box plots, in which the 
horizontal lines illustrate the 25th, 50th, and 75th percentiles of the MFI of NKG2D. The vertical 
lines represent the 10th and 90th percentiles. * P <10-4, ** P< 10-3  
B) Frequency of CD107a+ degranulating (left panel) or IFNγ-producing (right panel) NK cells 
incubated for 6 hr in medium alone, or in the presence of MHC class I-negative K562 cells 
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(E:T ratio 1:1). Results show the mean ± SEM values in 11 HCV patients and 15 healthy 
controls. * P = 0.003.  
C) Frequency of CD107a+ NK cells incubated for 6 hr with K562 cells (alone or in the 
presence of 20 μg/ml of NKG2D blocking mAb or control IgG), C1R cells or C1R-MICA 
transfectants. E:T ratio 1:1. Left panel: Combined data in 6 HCV patients (grey bars) and 6 
healthy controls (white bars). * P = 0.003, ** P = 0.0001. Right panel: Dot plots show a 
representative experiment in one control (upper line) and one HCV patient (lower line). 
Numbers in the quadrant indicate the percentage of CD107a+ NK cells.  
 
Figure 3: TGFβ is overproduced in HCV patients, and mediates NKG2D reduction on 
NK cells.  
A) The levels of total TGFβ were significantly higher in serum from 34 HCV patients 
compared to 23 controls (* P = 0.008).  Only 4 samples from SVR patients could be analyzed..  
B) Inverse correlation between serum TGFβ levels and NKG2D levels on NK cells in HCV 
patients. Pearson’s correlation coefficient r = - 0.49, P = 0.004.  
C) NKG2D levels are reduced in a TGFβ-dependent manner. NK cells were cultured in 
medium alone, or in medium containing 10% serum from representative HCV patients with 
known TGFβ concentration (S1: 6 ng/ml, i.e 0.6 ng/ml final concentration; S2: 32 ng/ml, i.e 
3.2 ng/ml final concentration), or in medium containing 10 ng/ml of recombinant TGFβ. 
NKG2D expression was analyzed 24 hr later by flow cytometry. Addition of 10 μg/ml of 
neutralizing anti-TGFβ  mAb during incubation largely reversed NKG2D reduction. Results 
are expressed as NKG2D levels on NK cells cultured in each indicated condition relative to the 
levels on NK cells cultured in medium alone, and represent mean ± SEM of 2 independent 
experiments. P = 0.02 for all comparisons (Kruskall Wallis test). 
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Figure 4: HCV-NS5A protein mediates TGFβ-induced downmodulation of NKG2D  
A) Control PBMCs (0.2 x 106/ml) were stimulated with HCV-core, -E2, -NS3, -NS4, -NS5A or 
β2 microglobulin proteins at 0.1 μg/ml (white bars), 0.5 μg/ml (gray bars), or 1 μg/ml (black 
bars), or with recombinant TGFβ (10 ng/ml) for 48h, and NKG2D expression was analyzed on 
CD3-CD56+ NK cells. Results are expressed as the percentage of inhibition of NKG2D 
expression in each condition relative to medium alone. Mean ± SEM of 3 independent 
experiments are shown. * P = 0.001. 
B) NS5A-mediated decrease in NK cell lytic potential. Control PBMCs were exposed to 
NS5A, NS4 or medium alone for  48 h, after which NK cell lytic potential to K562 target cells 
was evaluated by flow cytometry (CD107a expression). * P = 0.008. 
C) Kinetic analysis of TGFβ secretion upon 48 h stimulation of PBMCs (circles) or purified 
monocytes (squares) with 0.5 μg/ml of NS5A. TGFβ concentrations are given after 
background subtraction (cells cultured in medium alone). 
D) Pretreatment of PBMCs with increasing (0.01-3 μg/ml) concentrations of neutralizing 
TGFβ mAb prior to incubation with NS5A induces a dose-dependent increase of NKG2D on 
NK cells.  
E) Monocytes are the source of TGFβ upon NS5A stimulation. Left panel: The indicated cell 
populations were stimulated with 0.5 μg/ml of NS5A for 40 hr after which NKG2D expression 
was evaluated on NK cells. Results are expressed as NKG2D levels on NK cells in the 
indicated condition relative to the values in medium alone. NK cells were cultured with 
purified monocytes at the ratio of 1:1 with or without Transwell (0.4 μm) separation or in the 
presence of 10 μg/ml anti-TGFb mAb or isotype Ab. Data are mean ± SEM of 3 independent 
experiments. * P< 0.002 for comparison with the values in medium alone.  Right panel: 
Supernatants were harvested and assayed for TGFβ content. Values are normalized to TGFβ 
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produced by cells cultured  in medium alone and represent the mean ± SEM of 4 independent 
experiments. * P = 0.006, ** P = 0.0003.  
 
Figure 5: NS5A induces IL-10 and suppresses IL-12 production by monocytes through 
TLR4-mediated activation of p38 and PI3 kinase signaling.  
A) Left panel: Control monocytes (0.1 x 106/ml) were cultured in medium alone, or in the 
presence of NS4 (0.5 μg/ml), NS5A (0.5 μg/ml), LPS (1 μg/ml),  or NS5A+LPS for 24 hr, and 
cell supernatants were analyzed for IL-10 by ELISA. Data are expressed as the mean ± SEM of 
three independent experiments. * P = 0.01. Right panel: Monocytes were pretreated with IL-10 
neutralizing mAb or soluble IL-10 receptor prior to stimulation with NS5A, and TGFβ levels 
in the culture supernatants were quantified by ELISA. Results are expressed as index of 
inhibition of NS5A-mediated TGFβ levels, calculated as: [(TGFβ (NS5A) - TGFβ 
(NS5A+mAb))/ TGFβ (NS5A) - TGFβ (medium)]x100, and are the mean ± SEM of three 
independent experiments. * P = 0.02, ** P = 0.0005 
B) For IL-12p70 production, monocytes were first primed by IFNγ for 16 h and then stimulated 
with LPS (1 μg/ml), HCV-NS5A (0.5 μg/ml) or both for 24 hr, after which supernatants were 
analyzed for IL-12 by ELISA. Data are expressed as the mean ± SEM of three independent 
experiments. * P = 0.02, ** P = 0.001 
C) Purified monocytes were pretreated with 5 μg/ml of anti-TLR4, -TLR2 or -CD14 
neutralizing antibodies prior to 24 hr stimulation with 0.5 μg/ml of NS5A, after which IL-10 
levels in the supernatants were measured by ELISA. Results are the mean ± SEM of IL-10 
levels from mean replica values in 3 independent experiments. * P = 0.02, ** P= 0.01. 
D) Binding of NS5A to monocytes. Control monocytes were incubated for 30 min at 4°C with 
0.5 μg/ml of recombinant NS5A, NS4 or medium alone. Binding of NS5A to monocytes was  
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revealed by staining with anti-NS5A 9E10 antibody and flow cytometry analysis. Results are 
expressed as the percentage of positive cells, and are the mean of 4 independent experiments.  
E) Monocytes were left untreated, or treated with JNK inhibitor (SP600125, 10 μM), MEK 
inhibitor (U0126, 10 μM), PI3K inhibitor (LY294002, 1-50 μM), p38 inhibitor (SB203580, 
0.1-10 μM) or DMSO alone as negative control, for 1 hr prior to stimulation with NS5A (0.5 
μg/ml) for additional 24 h. Supernatants were assayed for IL-10 content by ELISA. Results 
represent the percentage of inhibition of IL-10 production, and are the mean ± SEM of 3 
separate experiments. * P < 0.01 
 
Figure 6 : Supernatants of HCV-infected Huh-7.5.1 cells reproduce the effect of 
recombinant NS5A.  
A) Control PBMCs were cultured for 48 hr in medium alone, in medium containing 0.5 μg/ml 
of recombinant NS5A, or in medium containing 50% of supernatant from non-infected or 
JFH1-replicating Huh-7.5.1 cells (collected at day 3, 13, 15 or 18 post transfection). NKG2D 
expression on NK cells was analyzed 48 hr later by flow cytometry. * P <0.05, ** P = 10-4 for 
comparison with the values in medium alone 
B) Control monocytes were incubated for 30 min at 4°C with supernatants from non-infected 
or JFH1-infected Huh-7.5.1 cells collected at the indicated day post infection, or with 
0.5 μg/ml of recombinant NS4 or NS5A proteins as negative and positive controls, 
respectively. Binding of NS5A to monocytes was  revealed by staining with anti-NS5A 9E10 
antibody and flow cytometry analysis. Results are expressed as the index of binding ([% 
binding with culture supernatant - % binding with medium alone] / % binding with medium 
alone), and represent mean ± SEM of 2 independent experiments.. 
C) NKG2D expression on liver-infiltrating NK cells from HCV patients.  Left panel: 
Representative NKG2D staining in paired circulating and liver-infiltrating NK cells freshly 
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isolated from one chronically-infected HCV patient. Dot plots and corresponding histograms 
show the frequency of NK cells (boxed CD3-CD56+) and their NKG2D expression. Right 
panel: NKG2D staining with anti-NKG2D mAb in liver biopsy from a chronically HCV-
infected patient. Results are representative of 4 HCV patients. Only few NKG2D-positive cells 
(arrows) are found within a mononuclear infiltrate surrounding a portal tract.  Original 
magnification, x40.  
 
Figure 7 : NS5A-induced alterations of NKG2D are antagonized by exogenous IL-15 
A) IL-15 and TGFβ are opposite effects on NKG2D levels. Left panel: NKG2D staining on 
NK cells from one HCV patient cultured for 48 days in medium alone or in the presence  of 10 
ng/ml of IL-15. Results are representative of  independent experiments in 3 patients.  
 Medium and right panels: PBMCs from one control were cultured in the presence of 10 ng/ml 
of IL-15 with or without NS5A (0.5 μg/ml) or TGFβ-containing serum (S2: 32 ng/ml). Results 
are representative of  independent experiments in 3 healthy controls.  
B) Purified NK cells from one HCV patient (upper panel) and one control (lower panel) were 
cultured for 36 hr with or without 10 ng/ml of IL-15 and/or 10 ng/ml TGFβ, after which lytic 
capacity to K562 target cells was measured. Numbers in the quadrant are the percentages of 
CD107a+ NK cells. Results are representative of 3 independent experiments.  
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Legends to Supporting Figures 
 
 
Figure S1 
CD107a expression on NK cells is positively correlated with NKG2D levels (Spearman rho 
(r) = 0.62, P = 0.008). 
 
Figure S2 
HCV-NS5A protein downregulates NKp30 levels on NK cells. Control PBMCs (0.2 x 106/ml) 
were cultured in medium alone (white bars) or in the presence of 0.5 μg/ml HCV-NS5A 
protein (black bars) for 48h, and NKp30 expression (MFI) was analyzed on CD3-CD56+ NK 
cells. Mean ± SEM values in 4 healthy controls. * P < 0.01. 
 
Figure S3 
NKG2D analysis in a representative liver sample. Freshly isolated liver infiltrating 
lymphocytes were stained with mAb to CD3, CD56 and NKG2D, or isotype control and 
analyzed by flow cytometry. A) Isotype control, B) CD3+ CD56- T lymphocytes , C) CD3-
CD56+ NK cells  
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Table 1 
Main characteristics of the patients 
       
Age (years)*    56 ± 2.5 [20-79]   
Gender (M/F)    18/16  
HCV genotype (n, %)   1  22 (64.7) 
      2 and 3 2 (5.9) 
      4  6 (17.6) 
      5  4 (11.8) 
Viral load (kUI/ml)*   1,169 ± 342 [0.6-8,000]  
ALT (xN)*    1.6 ± 0.15 [1-5] 
Liver fibrosis stage (n, %) 0-1 18 (53) 
    2 5 (14.7) 
    3 5 (14.7) 
    4 6 (17.6) 
Liver activity score (n, %) 0-1 26 (76.5) 
    2 2 (5.9) 
    3 6 (17.6) 
* expressed as mean  values ± standard error [range] 
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Accession numbers 
 
Name     Accession number  Entry name 
    (Swissprot) 
 
NKG2D   P26718   NKG2D_HUMAN 
Toll-like receptor 4  O00206   TLR4_HUMAN 
NS5 protein   Q81596   Q81596_9HEPC 
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